Moleculin Biotech stock fell 2.10 percent on October 5

Published on 10/06/2026 at 10:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moleculin Biotech stock was last at USD 0.48 on Nasdaq on October 5, 2026. The MIRACLE program enrolled 89 subjects, while Q2 net loss was USD 7.635 million.

MBRX, US60855D4088, Illustration mit AI erstellt.

Moleculin Biotech (ISIN US60855D4088) was last at USD 0.48 on Nasdaq on October 5, 2026 at 4:00 p.m. ET, down 2.10 percent from the prior close of USD 0.49. The company is now positioned around a larger clinical milestone after completing enrollment in Part A of its MIRACLE leukemia trial, a development reported on September 29, 2026.

MIRACLE reaches 89 subjects

According to StockTitan, Moleculin closed Part A with 89 subjects enrolled and one additional subject in screening on September 29, 2026. The randomized Phase 2/3 study compares two doses of Annamycin plus cytarabine with cytarabine plus placebo in adults with relapsed or refractory acute myeloid leukemia.

The company plans a comprehensive Part A efficacy and safety readout in the first quarter of 2027. That analysis matters because the trial measures all three arms after one treatment cycle, creating a concurrent control comparison rather than relying only on historical studies with multiple treatment cycles.

Cash and financing shape the timeline

As of June 30, 2026, Moleculin held USD 7.262 million in cash and equivalents, while second-quarter operating cash outflow was USD 6.657 million, according to StockTitan. The same filing summary says the company raised USD 9.3 million in gross proceeds after quarter-end and expects the combined funds to support operations into Q1 2027.

That funding profile gives the planned readout a clear financial constraint. The company also disclosed September ATM issuance of 888,400 shares for USD 0.48 million in gross proceeds in an SEC filing dated September 23, 2026, bringing common shares outstanding to 20,385,780.

Quarterly loss narrows

For Q2 2026, net loss was USD 7.635 million, compared with USD 17.809 million in Q2 2025, a 57.1 percent reduction. The figures come from Moleculin's Form 10-Q summary for the period ended June 30, 2026, published by MetaTrader.

For investors, the central comparison is between the clinical timetable and the funding runway. Enrollment is complete at 89 subjects, but the next major valuation test remains the data readout scheduled for Q1 2027.

MBRX stays below USD 1

MBRX was last at USD 0.48 on Nasdaq on October 5, 2026 at 4:00 p.m. ET. The 52-week range was USD 0.16-15.75, while market capitalization was USD 2.5 million and volume reached 467,150 shares.